Bli medlem
Bli medlem

Du är här


Karo Pharma: Annual General Meeting 2016 in Karo Pharma AB (publ)


STOCKHOLM, Sweden, May 12, 2016 - At today's Annual General Meeting in
Karo Pharma the following main resolutions were passed.

The AGM voted in favour of adopting the income statements and balance
sheets for the Group and the parent company, and decided that fund at
the disposal of the general meeting, amounting to SEK 359,757,654,
including the loss for the year amounting to SEK - 61,685,826, should
be carried forward. Thus, it was resolved that no dividend should be
paid for the financial year 2015.

The AGM further discharged the Board members and the CEO from
liability, re-elected the ordinary board members Anders Lönner,
Thomas Hedner, Per-Anders Johansson and Jean Lycke. Anders Lönner was
elected Chairman of the Board.

The AGM resolved that the Board shall consist of four ordinary members
and no deputy members.

The AGM further resolved in accordance with the Board's proposal on
amendment of the articles of association.

The AGM resolved that the Board's fees shall remain unchanged at SEK
420,000 for the Chairman of the Board and SEK 150,000 for each of the
other members of the Board.

The accounting firm PricewaterhouseCoopers AB was re-elected as the
company's auditor until the AGM 2017.

The AGM resolved in accordance with the proposal of the nomination
committee on principles for the nomination committee.

The AGM also resolved in accordance with the Board's proposal on
guidelines for remuneration of executive management.

Lastly, the Board was authorized to, on one or several occasions prior
to the next annual general, resolve on new share issues. The number
of shares to be issued by virtue of the authorization shall not
exceed 10 per cent of the registered share capital (at the time of
the share issue resolution). The new share may be made with our
without deviation from the shareholders' pre-emption right and with
or without terms of issue in kind or set-off or other terms.

For further information, please contact:
Henrik Palm, CFO, mobile phone +46 70 540 40 14 or e-mail

About Karo Pharma
Karo Pharma is a health care company focused on developing and
marketing of products to pharmacies, fast-moving consumer goods and
the fealth care directly. Karo Pharma is listed on Nasdaq Stockholm.

Karo Pharma publishes this information in accordance with the Swedish
Securities Markets Act. The information was submitted for publication
on May 12, 2016, at 9:00 pm CET.

This press release is also available at and


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.